Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 204 abstracts

no pagination
Tarn C, Godwin AK. The molecular pathogenesis of gastrointestinal stromal tumors . Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S7-17.
von Mehren M. Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies. Current oncology reports. 2006 May;8(3):192-7.
Wetherbee SL. New weapons to snuff out kidney cancer. Nursing. 2006 Dec;36(12 Pt.1):58-63; quiz 64.
Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Molecular Cancer Therapeutics. 2005 Mar;4(3):351-60.
Held-Warmkessel J. Managing three critical cancer complications. Nursing. 2005 Jan;35(1):58-63; quiz 63-4.
Manne SL, Ostroff JS, Winkel G, Fox K, Grana G, Miller E, Ross S, Frazier T, Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A, Morrow M, Chen JQ, Yager JD, Russo J, Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ, Devlin J, Sherman E, Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR, Murphy ME, Langer CJ, Mehta MP, Viterbo R, Greenberg RE, Al-Saleem T, Canutescu AA, Dunbrack RL, Serebriiskii IG, Fang R, Latypova E, Hopkins R, Vinson C, Joung JK, Golemis EA. Couple-focused group intervention for women with early stage breast cancer. . J Consult Clin Psychol. 2005 Sep 15;73(4):634-46.
Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clinical Colorectal Cancer. 2005 Jul;5(2):108-13.
Tarn C, Godwin AK. Molecular research directions in the management of gastrointestinal stromal tumors. Current treatment options in oncology. 2005 Nov;6(6):473-86.
Berger AC, Watson JC, Ross EA, Zalatoris A, Hoffman JP. Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma. Am Surg. 2004 Feb;70(2):169-73; discussion 173-4.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Einarson MB, Cukierman E, Compton DA, Golemis EA. Human enhancer of invasion-cluster, a coiled-coil protein required for passage through mitosis. Molecular and Cellular Biology. 2004 May;24(9):3957-71.
Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004 Mar;58(3):991-1002.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clinical lung cancer. 2004 Dec;6 Suppl 2:S85-8.
Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Ursulic S, Smyth J. Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer. 2003 Sep;39(13):1818-27.
Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003 Apr;21(7):1301-6.
Colice GL, Rubins J, Unger M. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest. 2003 Jan;123(1 Suppl):272S-283S.
Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, Daniel R, Skalka AM, Meropol NJ, Alberti C, Larue L, Bellacosa A. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A. 2003 Dec 09;100(25):15071-6.   PMCID: PMC299910
Eisenberg BL. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. Oncology (Huntingt). 2003 Nov;17(11):1615-20; discussion 1620, 1623, 1626 passim.
Eisenberg BL, von Mehren M. Pharmacotherapy of gastrointestinal stromal tumours. Expert Opin Pharmacother. 2003 Jun;4(6):869-74.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents Human therapeutic use 0 (Antineoplastic Agents) drug therapy dt [Drug Therapy] Pyrimidines Piperazines therapy Male metabolism Female Lung Neoplasms pharmacology genetics tu [Therapeutic Use] antagonists & inhibitors Middle Aged Non-Small-Cell Lung Carcinoma Aged surgery ch [Chemistry] Clinical Trials Treatment Outcome NIH Research Support-Extramural Gastrointestinal Stromal Tumors ai [Antagonists & Inhibitors] Mutation Neoadjuvant Therapy me [Metabolism] Adenocarcinoma Protein Kinase Inhibitors Neoplasm Drug Resistance methods Survival Rate pd [Pharmacology] US Gov't Support-PHS EC 2-7-1-112 (Protein-Tyrosine Kinase) Sequence Alignment Biological Tumor Markers Non-US Gov't Research Support Flow Cytometry ge [Genetics] Mitosis Cell Line Retrospective Studies Neoplasms Kidney Neoplasms Mice Enzyme Inhibitors Quinazolines Brain Neoplasms 0 (Taxoids) mortality Molecular Sequence Data ae [Adverse Effects] Colorectal Neoplasms Adult Time Factors Pancreatic Neoplasms Taxoids Platelet-Derived Growth Factor Receptors Apoptosis Protein-Tyrosine Kinase US Gov't Research Support-PHS diagnosis Western Blotting Monoclonal Antibodies Comparative Study Adjuvant Chemotherapy Protein Conformation Non-US Gov't Support Nephrectomy ph [Physiology] Proto-Oncogene Proteins c-kit Neoplasm Metastasis administration & dosage Saccharomyces cerevisiae 80 and over Aged Drug Delivery Systems Cisplatin Amino Acid Sequence Epidermal Growth Factor Receptor Immunotherapy Gastrointestinal Neoplasms Fibroblasts Molecular Models Small Interfering RNA Multivariate Analysis toxicity Adrenal Cortex Hormones Recombinant Fusion Proteins aa [Analogs & Derivatives] DNA Repair Local Neoplasm Recurrence Polyglutamic Acid Seizures pathology ep [Epidemiology] EC 27137 (Proto-Oncogene Proteins c-raf) Two-Hybrid System Techniques Catalytic Domain Binding Sites User-Computer Interface Serine Endopeptidases Immunohistochemistry Kinetics Proportional Hazards Models Systems Integration dosage Incidence ai [Antagonists & 951-77-9 (Deoxycytidine) Carrier Proteins Follow-Up Studies G2 Phase Thymine DNA Glycosylase Pyrroles Palliative Care Inappropriate ADH Syndrome et [Etiology] DNA-Binding Proteins Reverse Transcriptase Polymerase Chain Reaction etiology Complementary) 0 (DNA 184475-35-2 (gefitinib) Cultured Cells Analysis of Variance Algorithms physiopathology 0 (Recombinant Fusion Proteins) Neoplastic Gene Expression Regulation Randomized Controlled Trials Radiotherapy Alkyl and Aryl Transferases Cell Separation 0 (Adrenal Cortex Hormones) Cell Cycle Proteins Cognition Disorders Platelet-Derived Growth Factor) EC 2-7-1-112 (Receptors Antineoplastic Antimetabolites Drug Hypersensitivity ad [Administration & Dosage] Prognosis 0 (Piperazines) Survival Phytogenic Antineoplastic Agents 7689-03-4 (Camptothecin) Patient Education North America
Last updated on Friday, July 10, 2020